HER2/EGFR in Cancer Research
Peer reviewed
Scollr summary
What this paper is about
The meta-analysis shows that sacituzumab govitecan significantly improves PFS, OS, and ORR compared with standard chemotherapy in patients with HER2-negative breast cancer, reinforcing the role of SG as an effective treatment option for both metastatic TNBC and HR+/HER2- breast cancer.
Full abstract
Read the full abstract
OBJECTIVES: Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, has demonstrated clinical activity in HER2-negative breast cancer. Our meta-analysis aimed to evaluate the efficacy and safety of SG compared with standard chemotherapy in patients with breast cancer. METHODS: We conducted a comprehensive literature search across multiple databases for RCTs comparing SG with standard treatment in patients with breast cancer. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate (ORR), clinical benefit rate (CBR), disease control measures, and treatment-related adverse events. Hazard ratios (HRs), mean differences (MDs), and risk ratios (RRs) with 95% CIs were pooled using a random-effects model. RESULTS: Six RCTs encompassing 2481 patients were included. SG significantly improved PFS (HR=0.59), OS (HR=0.63), and ORR (RR=1.64) compared with chemotherapy. CBR was also significantly higher with SG (RR=1.89), and the rate of progressive disease was significantly lower (RR=0.62). Overall treatment-related adverse events were similar in both groups (RR=1.05). Neutropenia and diarrhea were significantly more frequent in the SG group. CONCLUSIONS: Our meta-analysis shows that sacituzumab govitecan significantly improves PFS, OS, and ORR compared with standard chemotherapy in patients with HER2-negative breast cancer. Although associated with higher rates of neutropenia and diarrhea, its overall safety profile remains manageable. These results reinforce the role of SG as an effective treatment option for both metastatic TNBC and HR+/HER2- breast cancer and support its continued evaluation in earlier treatment settings and combination strategies, including immunotherapy.
Direct answer
What can I do from this paper page?
Use this page to scan "Efficacy and Safety of Sacituzumab Govitecan for Breast Cancer" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow HER2/EGFR in Cancer Research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Tolentino2026Efficacy,
title = {Efficacy and Safety of Sacituzumab Govitecan for Breast Cancer},
author = {Lance G. Tolentino and Marharyta Khaustova and Reham Z. Alrwaitey and Asiya S. Chintala and Debasrita Baidya and Vutukuri Y. Kumar and Dalal Abdelrahim and Nnenna S.S. Ejiogu and Vanshika Bhardwaj and Breman A. Peethambar and Muhammad Ayyan},
journal = {American Journal of Clinical Oncology},
year = {2026},
doi = {10.1097/coc.0000000000001365},
url = {https://doi.org/10.1097/coc.0000000000001365}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new HER2/EGFR in Cancer Research papers?
Follow HER2/EGFR in Cancer Research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Efficacy and Safety of Sacituzumab Govitecan for Breast Cancer. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app